Phase I/II Clinical Study of 1A46 Drug Substance

Summary

A phase I/II, first in human, single arm, open label study to evaluate the safety and efficacy of the injection of triple-specific T-cell engager 1A46 in adult subjects with R/R CD20 positive and/or CD19 positive B cell non-Hodgkin's lymphoma (B - NHL)

Timeline

Start

2023-09-12

Primary completion

2024-08-20

Completion

2024-11-01

Outcome

Outcome not reported

Stopped (Business): “sponsor's Research and Development strategy adjustment”

Drugs

Indications